Cyanotech Corporation was founded in 1983 and is headquartered in Kailua-Kona, Hawaii. Cyanotech Corporation engages in the cultivation, production, and sale of natural products derived from microalgae worldwide. It offers BioAstin natural astaxanthin, a dietary antioxidant for use as a human nutraceutical and functional food ingredient to support and maintain the body's natural inflammatory response, as well as to enhance skin, muscle, and joint health. The company also provides Spirulina Pacifica, a nutrient-rich dietary supplement used for extra energy, as well as used as a strengthened immune system and source of antioxidant carotenoids. It sells its products to manufacturers, formulators, and distributors in the health foods and nutritional supplements markets; and to distributors, retailers, and direct consumers in the form of packaged consumer products. The company sells its products through online, as well as through resellers.

Lescarden Inc. was founded in 1960 and is based in New York, New York. Lescarden Inc. engages in the research, testing, and development of proprietary biologic materials with a focus on wound healing, clinical skin care, osteoarthritis, and cancer applications. The company offers CATRIX Wound Dressing, a powder derived from bovine cartilage for the management of chronic lesions and burns, as well as for non-healing wounds, such as decubitus ulcers, venous stasis ulcers, and diabetic ulcers. It also provides a line of Catrix-based skin care products for the plastic surgery, dermatology, and medical spa markets. In addition, the company offers nutritional supplements, including BIO-CARTILAGE; and POLY-Nag, a glucosamine polymer for the treatment of osteoarthritis. It also licenses its technologies for commercialization by other companies in Canada, Europe, and Korea. The company sells its products primarily in Europe, the Philippines, and Korea.

Cedarburg Hauser, formerly Cedarburg Pharmaceuticals, makes drugs, components of drugs, and ingredients for drugs. The contract manufacturer does everything from project management to manufacturing to validating study results. It produces custom chemicals, natural and synthetic active pharmaceutical ingredients, dietary supplements, and cosmetics. And, because Cedarburg Hauser also holds Drug Enforcement Agency permits, it makes controlled substances including pain killers and other narcotics. Other services include process development and a whole host of analytical services including quality control and stability studies.

Laboratorios Farmacéuticos ROVI manufactures and sells pharmaceuticals in Spain and the rest of Europe. Its best selling prescription drugs include Hibor, (a brand name heparin used to prevent blood clots during surgery), osteoporosis drug Osseor, and angina drug Corlentor. ROVI's handful of OTC products include Autan insect repellant and the Enerzona line of dietary wellness products.In 2009 the company licensed Novavax's VLP vaccine technology which it will use to create a flu vaccine for the Spanish government. The E60 million ($84 million) program is being sponsored by the Spanish Ministry of Health. ROVI was founded in 1946 and went public on the Spanish Stock Exchange in late 2007.

diaDexus, Inc. was founded in 1997 and is based in South San Francisco, California. diaDexus, Inc., a biotechnology company, engages in the discovery, development, and commercialization of in vitro diagnostic products to address the medical needs in the cardiovascular field. The company develops The PLAC Test, a blood test to aid in assessing risk for coronary heart disease (CHD) and ischemic stroke associated with atherosclerosis. Its product measures lipoprotein-associated phospholipase A2 (Lp-PLA2), which is a vascular-specific inflammatory enzyme implicated in the formation of rupture-prone plaque. The company’s PLAC Test is available as an ELISA assay that runs on an automated micropate system, as well as in the form of immunotarbidimetric technology that runs on common clinical chemistry analyzers used in clinical reference laboratories, hospitals, and physician office laboratories.

ASI Technology Corporation was incorporated in 1931 and is based in Henderson, Nevada. ASI Technology Corporation, together with its subsidiaries, operates as a specialty finance company. The company offers commercial and venture capital loans, as well as provides direct finance leasing services. It also focuses on the development of plasma technology for sterilization and decontamination. The company's patented method uses low voltage to produce high volumes of atmospheric pressure plasma, also known as room temperature or cold plasma.

Facet Biotech Corporation, a biotechnology company, engages in the identification and development of oncology therapeutics. Its products in development include Daclizumab, a monoclonal antibody in Phase II clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, which is in Phase I/II clinical studies is a chimeric monoclonal antibody that inhibits the functional activity of a protein in activated endothelial cells. The company is also developing Elotuzumab, a monoclonal antibody in Phase I clinical study, which binds to a cell surface glycoprotein that is expressed on myeloma cells and normal human cells; PDL192, a monoclonal antibody in Phase I clinical study, which binds to the tumor necrosis factor-like weak inducer of apoptosis receptor; and PDL241, a monoclonal antibody in the preclinical stage for immunologic diseases. Facet Biotech Corporation has a collaboration agreement with Biogen Idec Inc. The company is headquartered in Redwood City, California.

Eisai Inc. develops and markets pharmaceuticals to treat a variety of ills. As the US pharmaceutical production arm of Eisai Co., its current product roster includes Alzheimer's treatment Aricept, Aciphex for acid reflux, anticoagulant Fragmin, and anti-convulsant Zonegran. It also maintains an extensive pipeline of potential drugs to address cancer, epilepsy, and severe infection. Subsidiaries Eisai Research Institute of Boston and Eisai Medical Research conduct drug development efforts in areas including oncology, neurology, and gastrointestinal ailments.

Cortex Pharmaceuticals develops drugs to treat neurodegenerative and psychiatric disorders. Its research focuses on the AMPA receptor, which facilitates communication between nerve cells; the firm's Ampakine compounds may enhance this receptor's activity. Its lead drug candidate is CX717, which it is developing for a number of indications including respiratory depression (a potentially fatal side effect of some anesthetics and post-surgical painkillers), Alzheimer's disease, attention deficit hyperactivity disorder (ADHD), and daytime sleepiness. The firm believes Ampakine drugs may also be helpful in treating a variety of other brain-related disorders, including depression, autism, and Huntington's disease.

VIA Pharmaceuticals was founded in 2004 and is headquartered in San Francisco, California. VIA Pharmaceuticals, Inc., a development stage biotechnology company, focuses on the research and development of compounds for the treatment cardiovascular and metabolic diseases. The company is building a pipeline of small-molecule drugs that target inflammation in the blood vessel wall, an underlying cause of atherosclerosis and its complications, including heart attack and stroke. Its principal product, VIA-2291, is in Phase II clinical trials in patients with acute coronary syndrome and patients with stenosis of the carotid artery. The company has agreements with Hoffmann-LaRoche Inc. and Hoffmann-LaRoche Ltd. to develop and commercialize two sets of compounds for the treatment of cardiovascular and metabolic disease.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.